betahistine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	346	5638-76-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: betahistine dihydrochloride betahistine hydrochloride betahistine methanesulfonate betahistine dihydrobromide betahistine beta-histine betahistine mesilate merislon betahistine mesylate	A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers. Molecular weight: 136.20 Formula: C8H12N2 CLOGP: 0.08 LIPINSKI: 0 HAC: 2 HDO: 1 TPSA: 24.92 ALOGS: -0.44 ROTB: 3

Molecule

Description

Molfile Inchi Smiles

Synonyms:

betahistine dihydrochloride
betahistine hydrochloride
betahistine methanesulfonate
betahistine dihydrobromide
betahistine
beta-histine
betahistine mesilate
merislon
betahistine mesylate

A histamine analog and H1 receptor agonist that serves as a vasodilator. It is used in MENIERE DISEASE and in vascular headaches but may exacerbate bronchial asthma and peptic ulcers.

Molecular weight: 136.20
Formula: C8H12N2
CLOGP: 0.08
LIPINSKI: 0
HAC: 2
HDO: 1
TPSA: 24.92
ALOGS: -0.44
ROTB: 3

Drug dosage:

Dose	Unit	Route
24	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
S (Water solubility)	38 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ

Showing 1 to 2 of 2 entries

Previous1Next

Approvals:

None

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hyponatraemia	116.02	17.06	119	10963	111781	63366159
Parkinsonism	101.21	17.06	45	11037	10394	63467546
Pituitary tumour benign	95.22	17.06	28	11054	1967	63475973
Dizziness	87.24	17.06	215	10867	429710	63048230
Dementia	86.86	17.06	49	11033	18745	63459195
Enthesopathy	76.72	17.06	35	11047	8579	63469361
Hypoglycaemia	71.65	17.06	69	11013	59996	63417944
Multiple drug therapy	71.13	17.06	26	11056	3620	63474320
Fall	66.95	17.06	184	10898	392150	63085790
Syncope	66.89	17.06	92	10990	117293	63360647

Showing 1 to 10 of 91 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Oesophageal perforation	144.32	24.53	32	3774	1167	34951958
Soft tissue mass	143.85	24.53	31	3775	988	34952137
Multimorbidity	140.58	24.53	30	3776	912	34952213
Superinfection	115.96	24.53	31	3775	2488	34950637
Transplant failure	109.81	24.53	32	3774	3521	34949604
Immunosuppressant drug level increased	104.84	24.53	35	3771	6020	34947105
Oesophageal carcinoma	97.31	24.53	37	3769	9267	34943858
Inflammatory marker increased	94.80	24.53	31	3775	4997	34948128
Lung consolidation	89.75	24.53	31	3775	5905	34947220
Rales	74.38	24.53	31	3775	9852	34943273

Showing 1 to 10 of 31 entries

Previous1 2 3 4Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Soft tissue mass	115.49	16.91	30	14648	1258	79728452
Oesophageal perforation	114.24	16.91	31	14647	1540	79728170
Multimorbidity	107.47	16.91	29	14649	1410	79728300
Hyponatraemia	93.67	16.91	138	14540	177710	79552000
Hypoglycaemia	91.68	16.91	103	14575	101491	79628219
Pituitary tumour benign	90.79	16.91	29	14649	2547	79727163
Dizziness	90.48	16.91	256	14422	526185	79203525
Transplant failure	81.22	16.91	31	14647	4610	79725100
Superinfection	76.05	16.91	30	14648	4872	79724838
Parkinsonism	71.22	16.91	42	14636	16542	79713168

Showing 1 to 10 of 91 entries

Previous1 2 3 4 5…10Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N07CA01	NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS ANTIVERTIGO PREPARATIONS Antivertigo preparations
CHEBI has role	CHEBI:35620	vasodilator agents
CHEBI has role	CHEBI:71173	H1-receptor agonists
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D018494	Histamine Agents
MeSH PA	D017442	Histamine Agonists
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014665	Vasodilator Agents

Showing 1 to 8 of 8 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Ménière's disease	indication	13445001	DOID:9849

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.53	Basic
pKa2	3.77	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Histamine H3 receptor	GPCR	Q9Y5N1	HRH3_HUMAN	INVERSE AGONIST	EC50	9.52		SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Histamine H3 receptor	GPCR		HRH3_RAT		Ki	5.69		CHEMBL

Showing 1 to 2 of 2 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
000702	NDDF
004531	NDDF
005313	NDDF
006923	NDDF
11937	IUPHAR_LIGAND_ID
1502	INN_ID
1511	RXNORM
2366	PUBCHEM_CID
322052003	SNOMEDCT_US
350631001	SNOMEDCT_US

Showing 1 to 10 of 28 entries

Previous1 2 3Next

Pharmaceutical products:

None